Autopsy report · NCT00481936

Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin

“Corporate reasons unrelated to safety and efficacy”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 11 months before it stopped.
• 15 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Sesen Bio, Inc.

Sponsor type

Industry

Conditions

Neoplasms, Glandular and Epithelial

Interventions

VB6-845

Participants

15

Sites

6

Countries

Georgia, Russia

Trials that died the same way

• An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension
  “Business reasons unrelated to product safety” (81% match in meaning)
• Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
  “Business reasons not related to safety” (78% match in meaning)
• Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
  “Not related to safety concerns or lack of efficacy” (72% match in meaning)
• Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
  “Business reasons and not due to any safety concerns” (71% match in meaning)
• Investigational Study of Delayed Release Metformin
  “Strategic company decision - not related to a safety concern” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.